CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed
Drug / intervention
0.75 levonorgestrel +1 moredrug
Likely dose
50 mg ethinyl estradiol/0.5 mg levonorgestrelfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00204451
NCT00204451Phase 4Completed
CompareCT.gov

Human Ovarian Follicular Dynamics and Emergency Contraception

University of Saskatchewan·interventional·Posted Sep 20, 2005·Updated Nov 28, 2016

In Brief

A Phase 4 clinical trial evaluating 0.75 levonorgestrel and 50 mg ethinyl estradiol/0.5 mg levonorgestrel for Contraception. Completed, across 1 site.

Detailed Summary

The researchers hypothesize that emergency contraception (EC) will initiate the changes associated with atresia or ovulatory failure at all stages of follicular development and that the image attributes associated with atresia will be similar regardless of the diameter of the dominant follicle when ovarian suppression is initiated. Second, changes associated with atresia may be observed, but ovulation of the dominant follicle is unimpeded.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception
CountriesCanada
CollaboratorsCanadian Institutes of Health Research (CIHR)

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 20, 2005
Enrollment StartJul 1, 2005
Study CompletionJun 1, 2006
TodayJul 2, 2026
Posted 20.8 years ago

Interventions

0.75 levonorgestreldrug

50 mg ethinyl estradiol/0.5 mg levonorgestreldrug